DeepSeek is Driving Today’s Market: JG, HOLO, AKRO, MLGO, ONCO, and TVGN

January 27, 2025

DENVER, Colo., Jan 27, 2025 (247marketnews.com)- These are some of the hottest trades this morning and DeepSeek is this morning’s big news.

Aurora Mobile (NASDAQ: JG) made a strategic move in advancing its GPTBots.ai platform by integrating DeepSeek R1 large language model (LLM), further expanding its ecosystem of AI capabilities. With its array of LLMs, which includes models like OpenAI, Meta Llama, Mistral AI, Anthropic Claude, and Google Gemini, GPTBots.ai now offers even more flexibility and depth to its enterprise users.

Jerry Yin, VP of GPTBots.ai, stated, “The integration of DeepSeek R1 aligns perfectly with our mission to empower enterprises with advanced AI solutions and unmatched flexibility. With this expansion, GPTBots.ai continues to position itself as a leader in enterprise-focused AI, helping businesses navigate complex challenges while enhancing their operational efficiency and performance.

MicroCloud Hologram (NASDAQ: HOLO) is also riding the DeepSeek train by announcing that it made a significant leap in enhancing its holographic AI applications by adopting DeepSeek’s newly released R1 model. This decision is a strategic move aimed at advancing the company’s capabilities in the field of holographic digital content generation and interaction.

Akero Therapeutics (NASDAQ: AKRO) announced promising preliminary topline results from the SYMMETRY Phase 2b study, this morning. The study showcaased the potential of its lead product candidate, efruxifermin (EFX), in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). The results highlight a significant breakthrough, with 39% of patients in the 50mg EFX treatment group experiencing a reversal of cirrhosis without worsening of MASH, compared to just 15% in the placebo group (p=0.009). This data underscores EFX’s potential to offer a novel therapeutic approach for a condition that currently has limited treatment options.

Dr. Andrew Cheng, President and CEO of Akero, expressed enthusiasm about the findings, emphasizing the uniqueness of EFX in the MASH landscape. “We believe today’s first-ever public report of reversal of cirrhosis due to MASH, whether by completer or ITT analysis, sets EFX apart from other approved or investigational treatments,” Cheng said. The company is optimistic about the ongoing Phase 3 SYNCHRONY Outcomes study, which will further evaluate the efficacy and safety of 50mg EFX in patients with compensated cirrhosis due to MASH.

MicroAlgo (NASDAQ: MLGO), Onconetix (NASDAQ: ONCO), and Tevogen Bio (NASDAQ: TVGN) are also trading higher on much larger than usual volume.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (JG, HOLO, AKRO, MLGO, ONCO, TVGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.